Download PDF
Semin Thromb Hemost 2002; 28(s2): 015-024
DOI: 10.1055/s-2002-32313
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Selective Inhibition of Coagulation Factors: Advances in Antithrombotic Therapy

Kenneth A. Bauer
  • VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, Massachusetts
Further Information

Publication History

Publication Date:
19 June 2002 (online)

    Permissions and Reprints

ABSTRACT

Heparin and coumarin derivatives have long been used for the prophylaxis and treatment of venous thromboembolism (VTE). Although they have demonstrated efficacy and safety, they act at multiple targets within the coagulation cascade and their efficacy is influenced by many patient variables. Because of the need to improve the benefit-to-risk ratio of antithrombotic drugs, newer agents that target single coagulation factors have been developed. These include selective factor Xa inhibitors, direct thrombin inhibitors (DTIs), and inhibitors of factor IXa and the factor VII-tissue factor complex. Three DTIs-hirudin, bivalirudin, and argatroban-have been approved for clinical use. Fondaparinux, a novel pentasaccharide and the first selective factor Xa inhibitor to be approved by the U.S. Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products, is indicated for the prevention of VTE after major orthopedic surgery. Fondaparinux has predictable pharmacokinetics, is almost 100% bioavailable, and has a half-life that allows once-daily dosing in all indications. In addition, the routine monitoring of standard indicators of hemostasis is not required. The availability of these agents and the continued development of investigational selective coagulation inhibitors have the potential to improve efficacy and decrease adverse events in patients at risk for VTE.

KEYWORDS

Anticoagulants - fondaparinux - heparin - pentasaccharide - thrombosis

REFERENCES

  • 1 Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals from the Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association.  Circulation . 1996;  93 2212-2245
    CrossrefPubMedGoogle Scholar
  • 2 Giuntini C, Di Ricco G, Marini C, Melillo E, Palla A. Pulmonary embolism: epidemiology.  Chest . 1995;  3S-9S
    PubMedGoogle Scholar
  • 3 Hirsh J, Warkentin T E, Shaughnessy S G. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.  Chest . 2001;  119(Suppl) 64S-94S
    CrossrefPubMedGoogle Scholar
  • 4 Millenson M M, Bauer K A. Pathogenesis of venous thromboembolism. In: Hull R, Pineo GF, eds. Disorders of Thrombosis, 1st ed Philadelphia: WB Saunders Company 1996: 175-190
    Google Scholar
  • 5 Schafer A I, Ali N M, Levine G N. Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardiovascular Medicine, 6th ed Philadelphia: WB Saunders Company 2001: 2099-2132
    Google Scholar
  • 6 Boneu B, Schved J-F. La fédération italienne des cliniques d'anticoagulant. Guide to oral anticoagulant therapy (part 1) [in French].  Sang Thromb Vaiss . 1998;  10 291-313
    PubMedGoogle Scholar
  • 7 Beijering R JR, ten Cate H, ten Cate W J. Clinical applications of new antithrombotic agents.  Ann Hematol . 1996;  72 177-183
    CrossrefPubMedGoogle Scholar
  • 8 Diaz-Linares M, Rodvold K A. Coagulation disorders. In: DiPiro J, Talbert R, Yee G, et al, eds. Pharmacotherapy: A Pathophysiologic Approach, 4th ed Stamford, CT: Appleton & Lange 1999: 1549-1572
    Google Scholar
  • 9 Furie B, Furie B C. Molecular and cellular biology of blood coagulation.  N Engl J Med . 1992;  326 800-806
    CrossrefPubMedGoogle Scholar
  • 10 Iskander G P, Cheng E Y. Perioperative use of anticoagulants and thrombolytics.  Anesthesiol Clin North Am . 1999;  17 715-731
    PubMedGoogle Scholar
  • 11 Rosenberg R D, Aird W C. Vascular-bed-specific hemostasis and hypercoagulable states.  N Engl J Med . 1999;  340 1555-1564
    CrossrefPubMedGoogle Scholar
  • 12 Esmon C T. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.  Crit Care Med . 2001;  29(Suppl 7) S48-S51
    PubMedGoogle Scholar
  • 13 McVey J H. Tissue factor pathway.  Baillieres Best Pract Res Clin Haematol . 1999;  12 361-372
    CrossrefPubMedGoogle Scholar
  • 14 Bajaj M S, Birktoft J J, Steer S A, Bajaj S P. Structure and biology of tissue factor pathway inhibitor.  Thromb Haemost . 2001;  86 959-972
    Google Scholar
  • 15 Wiman B. The fibrinolytic enzyme system. Basic principles and links to venous and arterial thrombosis.  Hematol Oncol Clin North Am . 2000;  14 325-338
    PubMedGoogle Scholar
  • 16 Billett H H. Direct and indirect antithrombins. Heparins, low molecular weight heparins, heparinoids, and hirudin-thromboembolic disease and anticoagulation in the elderly.  Clin Geriatr Med . 2001;  17 15-21
    PubMedGoogle Scholar
  • 17 Andersson L-O, Barrowcliffe T W, Holmer E, Johnson E A, Sims G EC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration.  Thromb Res . 1976;  9 575-583
    CrossrefPubMedGoogle Scholar
  • 18 Hirsh J. Heparin.  N Engl J Med . 1991;  324 1565-1574
    CrossrefPubMedGoogle Scholar
  • 19 Lam L H, Silbert J E, Rosenberg R D. The separation of active and inactive forms of heparin.  Biochem Biophys Res Commun . 1976;  69 570-577
    CrossrefPubMedGoogle Scholar
  • 20 Holmer E, Soderstrom G, Andersson L O. Studies on the mechanism of the rate-enhancing effect of heparin on the thrombin-antithrombin III reaction.  Eur J Biochem . 1979;  93 1-5
    CrossrefPubMedGoogle Scholar
  • 21 Lane D A, Denton J, Flynn A M, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.  Biochem J . 1984;  218 725-732
    PubMedGoogle Scholar
  • 22 Lindahl U, Backstrom G, Thunberg L. The antithrombin-binding sequence in heparin. Identification of an essential 6-O-sulfate group.  J Biol Chem . 1983;  258 9826-9830
    PubMedGoogle Scholar
  • 23 Liaw P CY, Austin R C, Fredenburgh J C, Stafford A R, Weitz J I. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.  J Biol Chem . 1999;  274 27597-27604
    CrossrefPubMedGoogle Scholar
  • 24 Hirsh J, Anand S S, Halperin J L, Fuster V. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association.  Circulation . 2001;  103 2994-3018
    CrossrefPubMedGoogle Scholar
  • 25 Eika C. Inhibition of thrombin induced aggregation of human platelets by heparin.  Scand J Haematol . 1971;  8 216-222
    PubMedGoogle Scholar
  • 26 Eika C. Inhibition of thrombin-induced aggregation of human platelets by heparin and antithrombin 3.  Scand J Haematol . 1971;  8 250-256
    PubMedGoogle Scholar
  • 27 Lupu C, Poulsen E, Roquefeuil S. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture.  Arterioscler Thromb Vasc Biol . 1999;  19 2251-2262
    Google Scholar
  • 28 Weitz J I. Low-molecular-weight heparins.  N Engl J Med . 1997;  337 688-698
    CrossrefPubMedGoogle Scholar
  • 29 Hirsh J. From unfractionated heparins to low molecular weight heparins.  Acta Chir Scand . 1990;  156(Suppl 556) 42-50
    PubMedGoogle Scholar
  • 30 Choay J, Petitou M, Lormeau J C. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity.  Biochem Biophys Res Commun . 1983;  116 492-499
    PubMedGoogle Scholar
  • 31 Schafer A I. Low-molecular-weight heparin-an opportunity for home treatment of venous thrombosis.  N Engl J Med . 1996;  334 724-725
    CrossrefPubMedGoogle Scholar
  • 32 Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina.  Circulation . 1998;  98 1575-1582
    PubMedGoogle Scholar
  • 33 Majerus P W, Broze Jr J G, Miletich J P, Tollefsen D M. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 9th ed New York: McGraw-Hill 1995: 1341-1359
    Google Scholar
  • 34 Hirsh J, Dalen J E, Anderson D R. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest . 2001;  119 8S-21S
    CrossrefPubMedGoogle Scholar
  • 35 Hirsh J. Oral anticoagulant drugs.  N Engl J Med . 1991;  324 1865-1875
    CrossrefPubMedGoogle Scholar
  • 36 Hirsh J, Dalen J E, Anderson D R. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest . 1998;  114(Suppl 5) 445S-469S
    CrossrefPubMedGoogle Scholar
  • 37 Herbert J M, Petitou M, Lormeau J C. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent.  Cardiovasc Drug Rev . 1997;  15 1-26
    PubMedGoogle Scholar
  • 38 Walenga J M, Jeske W P, Bara L, Samama M M, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.  Thromb Res . 1997;  86 1-36
    CrossrefPubMedGoogle Scholar
  • 39 van Boeckel A A C, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics.  Angew Chem Int Ed Engl . 1993;  32 1671-1690
    PubMedGoogle Scholar
  • 40 Turpie A GG, Gallus A S, Hoek J A, for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.  N Engl J Med . 2001;  344 619-625
    CrossrefPubMedGoogle Scholar
  • 41 Walenga J M, Bara L, Petitou M. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.  Thromb Res . 1988;  51 23-33
    CrossrefPubMedGoogle Scholar
  • 42 Donat F, Duret J P, Santoni A. Pharmacokinetics of Org31540/SR90107A in young and elderly healthy subjects: a highly favourable pharmacokinetic profile [abstract P3094]. Thromb Haemost 2001;July(Suppl). Available on CD-ROM published by Excerpta Medica Medical Communications
    Google Scholar
  • 43 Lormeau J C, Herault J P. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa.  Thromb Haemost . 1995;  74 1474-1477
    PubMedGoogle Scholar
  • 44 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med . 1995;  332 1330-1335
    CrossrefPubMedGoogle Scholar
  • 45 Elalamy I, LeCrubier C, Potevin F. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia [letter].  Thromb Haemost . 1995;  74 1384-1385
    PubMedGoogle Scholar
  • 46 Amiral J, Lormeau J C, Marfaing-Koka A. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.  Blood Coagul Fibrinolysis . 1997;  8 114-117
    PubMedGoogle Scholar
  • 47 Waxman L, Smith D E, Arcuri K E, Vlasuk G P. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa.  Science . 1990;  248 593-596
    CrossrefPubMedGoogle Scholar
  • 48 Jordan S P, Waxman L, Smith D E, Vlasuk G P. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa.  Biochemistry . 1990;  29 11095-11100
    CrossrefPubMedGoogle Scholar
  • 49 Vlasuk G P, Ramjit D, Fujita T. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis.  Thromb Haemost . 1991;  65 257-262
    PubMedGoogle Scholar
  • 50 Dunwiddie C, Thornberry N A, Bull H G. Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site.  J Biol Chem . 1989;  264 16694-16699
    PubMedGoogle Scholar
  • 51 Tuszynski G P, Gasic T B, Gasic G J. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation.  J Biol Chem . 1987;  262 9718-9723
    PubMedGoogle Scholar
  • 52 Faria F, Kelen E M, Sampaio C A. A new factor Xa inhibitor (lefaxin) from the Haementeria depressa leech.  Thromb Haemost . 1999;  82 1469-1473
    PubMedGoogle Scholar
  • 53 Herbert J M, Bernat A, Dol F. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.  J Pharmacol Exp Ther . 1996;  276 1030-1038
    PubMedGoogle Scholar
  • 54 Rogers K L, Chi L, Rapundalo S T, Kramer J B, Gallagher K P. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.  Basic Res Cardiol . 1999;  94 15-22
    CrossrefPubMedGoogle Scholar
  • 55 Murayama N, Tanaka M, Kunitada S. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.  Clin Pharmacol Ther . 1999;  66 258-264
    PubMedGoogle Scholar
  • 56 Hirsh J. New anticoagulants.  Am Heart J . 2001;  142 S3-S8
    CrossrefPubMedGoogle Scholar
  • 57 Stone S R, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin.  Biochemistry . 1986;  25 4622-4628
    CrossrefPubMedGoogle Scholar
  • 58 Ansell J E, Weitz J I, Comerota A J. Advances in therapy and the management of antithrombotic drugs for venous thromboembolism. In: Hematology 2000 Washington, DC: American Society of Hematology 2000: 266-284
    Google Scholar
  • 59 Eriksson B I, Wille-Jørgensen P, Kälebo P. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med . 1997;  337 1329-1335
    CrossrefPubMedGoogle Scholar
  • 60 Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.  N Engl J Med . 1996;  335 775-782
    CrossrefPubMedGoogle Scholar
  • 61 Scatena R. Bivalirudin: a new generation antithrombotic drug.  Expert Opin Investig Drugs . 2000;  9 1119-1127
    CrossrefPubMedGoogle Scholar
  • 62 Maraganore J M, Bourdon P, Jablonski J, Ramachandran K L, Fenton J W. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.  Biochemistry . 1990;  29 7095-7101
    CrossrefPubMedGoogle Scholar
  • 63 Witting J I, Bourdon P, Brezniak D V, Maraganore J M, Fenton J W. Thrombin-specific inhibition by and slow cleavage of hirulog-1.  Biochem J . 1992;  283(Pt 3) 737-743
    PubMedGoogle Scholar
  • 64 Bates S M, Weitz J I. The mechanism of action of thrombin inhibitors.  J Invasive Cardiol . 2000;  12(Suppl F) 27F-32F
    PubMedGoogle Scholar
  • 65 Bittl J A, Strony J, Brinker J A. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina.  N Engl J Med . 1995;  333 764-769
    CrossrefPubMedGoogle Scholar
  • 66 Sanderson P E. Small, noncovalent serine protease inhibitors.  Med Res Rev . 1999;  19 179-197
    CrossrefPubMedGoogle Scholar
  • 67 Bates S M, Weitz J I. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.  Am J Cardiol . 1998;  82 12P-18P
    CrossrefPubMedGoogle Scholar
  • 68 Jang I-K, Brown D FM, Giugliano R P. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study.  J Am Coll Cardiol . 1999;  33 1879-1885
    CrossrefPubMedGoogle Scholar
  • 69 Heit J A, Colwell C W, Francis C W. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. A phase 2 dose-finding study.  Arch Intern Med . 2001;  161 2215-2221
    CrossrefPubMedGoogle Scholar
  • 70 Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study.  Eur Heart J . 1997;  18 1416-1425
    PubMedGoogle Scholar
  • 71 Hirsh J. Modulating the coagulation cascade: new targets for antithrombotics and anticoagulants.  Am Heart J . 2001;  142 S1-S2
    CrossrefPubMedGoogle Scholar
  • 72 Bernard G R, Vincent J-L, Laterre P-F. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med . 2001;  344 699-709
    CrossrefPubMedGoogle Scholar
  • 73 Alberio L, Lämmle B, Esmon C T. Protein C replacement in severe meningococcemia: rationale and clinical experience.  Clin Infect Dis . 2001;  32 1338-1346
    CrossrefPubMedGoogle Scholar
  • 74 Spanier T B, Oz M C, Minanov O P. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.  J Thorac Cardiovasc Surg . 1998;  115 1179-1188
    PubMedGoogle Scholar
  • 75 Benedict C R, Ryan J, Wolitzky B. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.  J Clin Invest . 1991;  88 1760-1765
    PubMedGoogle Scholar
  • 76 Feuerstein G Z, Toomey J R, Valocik R. An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis.  Thromb Haemost . 1999;  82 1443-1445
    PubMedGoogle Scholar
  • 77 Toomey J R, Blackburn M N, Storer B L. Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis.  Thromb Res . 2000;  100 73-79
    CrossrefPubMedGoogle Scholar
  • 78 Hedner U, Erhardtsen E. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI.  Ann Med . 2000;  32(Suppl 1) 68-72
    PubMedGoogle Scholar
  • 79 Creasey A A, Reinhart K. Tissue factor pathway inhibitor activity in severe sepsis.  Crit Care Med . 2001;  S126-S129
    PubMedGoogle Scholar
  • 80 Rubin B G, Toursarkissian B, Petrinec D. Preincubation of Dacron grafts with recombinant tissue factor pathway inhibitor decreases their thrombogenicity in vivo.  J Vasc Surg . 1996;  24 865-870
    PubMedGoogle Scholar
  • 81 Duggan B M, Dyson H J, Wright P E. Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2.  Eur J Biochem . 1999;  265 539-548
    CrossrefPubMedGoogle Scholar